Clinical application of Apatinib in the treatment of malignancies

doi:10.3760/cma.j.issn.1673-422X.2019.01.010

Abstract

Abstract: Apatinib is a kind of antiangiogenesis drug of small molecular tyrosine kinase inhibitor, which can strongly against tumor angiogenesis by inhibiting vascular endothelial growth factor receptor 2 with highly selectivity. Apatinib can block cell cycle and reverse drug resistance. Clinical studies have shown that Apatinib is effective for many malignant tumors, including non-small-cell lung cancer, breast cancer and gastric cancer, which has encouraging objective response rate and survival benefit. Apatinib also has good safety and tolerance.

Key words: Neoplasms, Neovascularization, pathologic, Apatinib, Vascular endothelial growth factor receptor-2, Molecular targeted therapy

Huang Hai, Bi Feng. Clinical application of Apatinib in the treatment of malignancies[J]. Journal of International Oncology, 2019, 46(1): 45-48.

References

［1］ Roviello G, Ravelli A, Polom K, et al. Apatinib: a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer［J］. Cancer Lett, 2016, 372(2): 187-191. DOI: 10.1016/j.canlet.2016.01.014. ［2］秦叔逵, 李进. 阿帕替尼治疗胃癌的临床应用专家共识［J］. 临床肿瘤学杂志, 2015, 20(9): 841-847. ［3］ Scott AJ, Messersmith WA, Jimeno A. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors［J］. Drugs Today (Barc), 2015, 51(4): 223-229. DOI: 10.1358/dot.2015.51.4.2320599. ［4］ Pinto MP, Owen GI, Retamal I, et al. Angiogenesis inhibitors in early development for gastric cancer［J］. Expert Opin Investig Drugs, 2017, 26(9): 1007-1017. DOI: 10.1080/13543784.2017.1361926. ［5］ Siemann DW, Chaplin DJ, Horsman MR. Realizing the potential of vascular targeted therapy: the rationale for combining vascular disrupting agents and antiangiogenic agents to treat cancer［J］. Cancer Invest, 2017, 35(8): 519534. DOI: 10.1080/07357907.2017.1364745. ［6］ Karasic TB, Rosen MA, O′Dwyer PJ. Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?［J］. Cancer Chemother Pharmacol, 2017, 80(4): 661-671. DOI: 10.1007/s00280-017-3389-3. ［7］ Zhang H. Apatinib for molecular targeted therapy in tumor［J］. Drug Des Devel Ther, 2015, 9: 6075-6081. DOI: 10.2147/DDDT.S97235. ［8］ Lee SH, Jeong D, Han YS, et al. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis［J］. Ann Surg Treat Res, 2015, 89(1): 1-8. DOI: 10.4174/astr.2015.89.1.1. ［9］殷亮, 王荩, 黄凤昌, 等. 甲磺酸阿帕替尼对结肠癌HCT116细胞增殖的抑制作用及其机制［J］. 南方医科大学学报, 2017, 37(3): 367-372. DOI: 10.3969/j.issn.1673-4254.2017.03.15. ［10］ Rahimi N. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials［J］. Exp Eye Res, 2006, 83(5): 1005-1016. DOI: 10.1016/j.exer.2006.03.019 ［11］李彤, 翟二涛, 许丽霞, 等. 阿帕替尼通过阻断VEGF通路增强胃癌放疗疗效［J］. 中国病理生理杂志, 2017, 33(5): 776-781. DOI: 10.3969/j.issn.1000-4718.2017.05.002. ［12］ Mi YJ, Liang YJ, Huang HB, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATPbinding cassette transporters［J］. Cancer Res, 2010, 70(20): 7981-7991. DOI: 10.1158/0008-5472.CAN-10-0111 ［13］ Tong XZ, Wang F, Liang S, et al. Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1overexpressing leukemia cells［J］. Biochem Pharmacol, 2012, 83(5): 586-597. DOI: 10.1016/j.bcp.2011.12.007. ［14］ Li J, Zhao X, Chen L, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor2 inhibitor YN968D1 in patients with advanced malignancies［J］. BMC Cancer, 2010, 10: 529. DOI: 10.1186/1471-2407-10-529. ［15］ Li J, Qin S, Xu J, et al. Apatinib for chemotherapyrefractory advanced metastatic gastric cancer: results from a randomized, placebocontrolled, parallelarm, phase Ⅱ trial［J］. J Clin Oncol, 2013, 31(26): 3219-3225. DOI: 10.1200/JCO.2013.48.8585. ［16］ Li J, Qin S, Xu J, et al. Randomized, doubleblind, placebocontrolled phase Ⅲ trial of apatinib in patients with chemotherapyrefractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction［J］. J Clin Oncol, 2016, 34(13): 1448-1454. DOI: 10.1200/JCO.2015.63.5995. ［17］ Geng R, Li J. Apatinib for the treatment of gastric cancer［J］. Expert Opin Pharmacother, 2015, 16(1): 117-122. DOI: 10.1517/14656566.2015.981526. ［18］ Li F, Zhu T, Cao B, et al. Apatinib enhances antitumour activity of EGFRTKIs in nonsmall cell lung cancer with EGFRTKI resistance［J］. Eur J Cancer, 2017, 84: 184-192. DOI: 10.1016/j.ejca.2017.07.037. ［19］ Hu X, Zhang J, Xu B, et al. Multicenter phase Ⅱ study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triplenegative breast cancer［J］. Int J Cancer, 2014, 135(8): 1961-1969. DOI: 10.1002/ijc.28829. ［20］ Hu X, Cao J, Hu W, et al. Multicenter phase Ⅱ study of apatinib in nontriplenegative metastatic breast cancer［J］. BMC Cancer, 2014, 14: 820. DOI: 10.1186/1471-2407-14820. ［21］ Fan M, Zhang J, Wang Z, et al. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGFdependency of advanced breast cancer in antiangiogenic therapy［J］. Breast Cancer Res Treat, 2014, 143(1): 141-151. DOI: 10.1007/s10549-013-2793-6. ［22］ Qin SK. Apatinib in Chinese patients with advanced hepatocellular carcinoma: a phase Ⅱ randomized, openlabel trial［J］. J Clin Oncol, 2014, 32(15 Suppl): 4019. DOI: 10.1200/jco.2014.32.15_suppl.4019. ［23］ Yu WC, Zhang KZ, Chen SG, et al. Efficacy and safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: a prospective observation study［J］. Medicine (Baltimore), 2018, 97(3): e9704. DOI: 10.1097/MD.0000000000009704. ［24］ Lu W, Jin XL, Yang C, et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a singlecenter randomized controlled trial［J］. Cancer Biol Ther, 2017, 18(6): 433-438. DOI: 10.1080/15384047.2017.1323589. ［25］ Li F, Liao Z, Zhao J, et al. Efficacy and safety of apatinib in stage Ⅳ sarcomas: experience of a major sarcoma center in China［J］. Oncotarget, 2017, 8(38): 64471-64480. DOI: 10.18632/oncotarget.16293. ［26］ Zhu B, Li J, Xie Q, et al. Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: an observational study［J］. Cancer Biol Ther, 2018, 19(3): 198-204. DOI: 10.1080/15384047.2017.1416275. ［27］ Liu K, Ren T, Huang Y, et al. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL2 signaling in osteosarcoma［J］. Cell Death Dis, 2017, 8(8): e3015. DOI: 10.1038/cddis.2017.422. ［28］ Zheng B, Ren T, Huang Y, et al. Apatinib inhibits migration and invasion as well as PDL1 expression in osteosarcoma by targeting STAT3［J］. Biochem Biophys Res Commun, 2018, 495(2): 1695-1701. DOI: 10.1016/j.bbrc.2017.12.032. ［29］ Li J, Wang L. Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma［J］. Onco Targets Ther, 2017, 10: 3965-3969. DOI: 10.2147/OTT.S132756. ［30］ Liang L, Wang L, Zhu P, et al. A pilot study of apatinib as thirdline treatment in patients with heavily treated metastatic colorectal cancer［J］. Clin Colorectal Cancer, 2018, 17(3): e443e449. DOI: 10.1016/j.clcc.2018.02.011. ［31］林岩松, 王宸, 李慧, 等. 甲磺酸阿帕替尼治疗进展性碘难治性甲状腺癌的短期疗效及安全性初步报告［J］. 中国癌症杂志, 2016, 26(9): 721-726. DOI: 10.19401/j.cnki.1007-3639.2016.09.001. ［32］ Zhang M, Tian Z, Sun Y. Successful treatment of ovarian cancer with apatinib combined with chemotherapy: a case report［J］. Medicine (Baltimore), 2017, 96(45): e8570. DOI: 10.1097/MD.0000000000008570. ［33］Li CM, Liu ZC, Bao YT, et al. Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: a case report and literature review［J］. World J Gastroenterol, 2017, 23(41): 7478-7488. DOI: 10.3748/wjg.v23.i41.7478. ［34］Ji G, Hong L, Yang P. Successful treatment of advanced malignant fibrous histiocytoma of the right forearm with apatinib: a case report［J］. Onco Targets Ther, 2016, 9: 643-647. DOI: 10.2147/OTT.S96133. ［35］ Bi J, Liu H, Huang Y. The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature［J］. Int Med Case Rep J, 2017, 10: 223-227. DOI: 10.2147/IMCRJ.S137484 ［36］Zhang H, Chen F, Wang Z, et al. Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series［J］. Onco Targets Ther, 2017, 10: 837-845. DOI: 10.2147/OTT.S119129. ［37］Luo C, Shen J, Ying J, et al. Case report of a KITmutated melanoma patient with an excellent response to apatinib and temozolomide combination therapy［J］. Onco Targets Ther, 2017, 10: 4553-4557. DOI: 10.2147/OTT.S146409. ［38］Li XF, Tan YN, Cao Y, et al. A case report of gastrointestinal hemorrhage and perforation during apatinib treatment of gastric cancer［J］. Medicine (Baltimore), 2015, 94(39): e1661. DOI: 10.1097/MD.0000000000001661.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.